Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
Vir Biotechnology, Inc. (VIR) had Normalized Pre-Tax Income of $-110.79M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
$1.21M |
|
$-110.96M |
|
$0.01M |
|
$1.20M |
|
$119.63M |
|
$-118.42M |
|
$7.63M |
|
$-110.79M |
|
|
Normalized Pre-Tax Income |
$-110.79M |
$-110.96M |
|
$-110.96M |
|
$-110.96M |
|
$-110.96M |
|
$-118.42M |
|
$-112.98M |
|
138.45M |
|
138.45M |
|
$-0.80 |
|
$-0.80 |
|
| Balance Sheet Financials | |
$735.71M |
|
$60.80M |
|
$456.83M |
|
$1.19B |
|
$105.00M |
|
-- |
|
$140.06M |
|
$245.06M |
|
$947.47M |
|
$922.54M |
|
$947.47M |
|
138.89M |
|
| Cash Flow Statement Financials | |
$-198.34M |
|
$183.27M |
|
$2.64M |
|
$318.69M |
|
$306.28M |
|
$-12.42M |
|
$26.51M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.01 |
|
-- |
|
-- |
|
-- |
|
-- |
|
99.09% |
|
-9754.28% |
|
-9754.28% |
|
-- |
|
-9125.86% |
|
-9139.87% |
|
$-202.18M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-11.71% |
|
-12.03% |
|
-9.30% |
|
-11.71% |
|
$6.82 |
|
$-1.46 |
|
$-1.43 |
|